Novozymes As Stock EBITDA
| NVZMY Stock | USD 59.38 1.92 3.34% |
Novozymes AS fundamentals help investors to digest information that contributes to Novozymes' financial success or failures. It also enables traders to predict the movement of Novozymes Pink Sheet. The fundamental analysis module provides a way to measure Novozymes' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Novozymes pink sheet.
Novozymes |
Novozymes AS Company EBITDA Analysis
Novozymes' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Novozymes EBITDA | 6.11 B |
Most of Novozymes' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Novozymes AS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
According to the company disclosure, Novozymes AS reported earnings before interest,tax, depreciation and amortization of 6.11 B. This is much higher than that of the Basic Materials sector and significantly higher than that of the Specialty Chemicals industry. The ebitda for all United States stocks is 56.6% lower than that of the firm.
Novozymes EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Novozymes' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Novozymes could also be used in its relative valuation, which is a method of valuing Novozymes by comparing valuation metrics of similar companies.Novozymes is currently under evaluation in ebitda category among its peers.
Novozymes Fundamentals
| Return On Equity | 0.28 | |||
| Return On Asset | 0.11 | |||
| Profit Margin | 0.21 % | |||
| Operating Margin | 0.26 % | |||
| Current Valuation | 14.47 B | |||
| Shares Outstanding | 276.6 M | |||
| Price To Earning | 34.25 X | |||
| Price To Book | 6.12 X | |||
| Price To Sales | 0.80 X | |||
| Revenue | 17.55 B | |||
| Gross Profit | 9.59 B | |||
| EBITDA | 6.11 B | |||
| Net Income | 3.69 B | |||
| Cash And Equivalents | 1.01 B | |||
| Cash Per Share | 3.67 X | |||
| Total Debt | 7.31 B | |||
| Debt To Equity | 0.58 % | |||
| Current Ratio | 1.20 X | |||
| Book Value Per Share | 50.02 X | |||
| Cash Flow From Operations | 4.01 B | |||
| Earnings Per Share | 1.90 X | |||
| Price To Earnings To Growth | 3.81 X | |||
| Target Price | 51.26 | |||
| Number Of Employees | 6.44 K | |||
| Beta | 0.4 | |||
| Market Capitalization | 14.41 B | |||
| Total Asset | 27.98 B | |||
| Retained Earnings | 9.99 B | |||
| Working Capital | 2.67 B | |||
| Current Asset | 6.08 B | |||
| Current Liabilities | 3.41 B | |||
| Z Score | 0.6 | |||
| Annual Yield | 0.02 % | |||
| Five Year Return | 1.38 % | |||
| Net Asset | 27.98 B | |||
| Last Dividend Paid | 6.0 |
About Novozymes Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Novozymes AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novozymes using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novozymes AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Novozymes Pink Sheet Analysis
When running Novozymes' price analysis, check to measure Novozymes' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novozymes is operating at the current time. Most of Novozymes' value examination focuses on studying past and present price action to predict the probability of Novozymes' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novozymes' price. Additionally, you may evaluate how the addition of Novozymes to your portfolios can decrease your overall portfolio volatility.